| A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) (NCT04875195) | Merck Sharp & Dohme LLC | 2021-06-07 |
| Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT03776864) | University of Washington | 2019-09-26 |
| A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma (NCT03722147) | Akeso | 2018-08-13 |
| The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD (NCT03615664) | Polish Lymphoma Research Group | 2017-11-06 |
| Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders (NCT03198234) | Roncarolo, Maria Grazia, MD | 2017-08-30 |
| A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma (NCT03343652) | St. Petersburg State Pavlov Medical University | 2017-05-27 |
| CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (NCT02917083) | Baylor College of Medicine | 2017-05-08 |
| Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma (NCT02613598) | University of Michigan Rogel Cancer Center | 2016-05-12 |
| Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies (NCT02576496) | Mundipharma Research Limited | 2016-04-14 |
| Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation (NCT02719821) | University of Wisconsin, Madison | 2016-03-01 |
| Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma (NCT02722733) | Maria Sklodowska-Curie National Research Institute of Oncology | 2016-03-01 |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (NCT02593123) | Virginia Commonwealth University | 2015-11-04 |
| Reduced Intensity Conditioning Transplant Using Haploidentical Donors (NCT02581007) | Northside Hospital, Inc. | 2015-10-26 |
| Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (NCT02356159) | National Cancer Institute (NCI) | 2015-09-24 |
| Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) (NCT02408042) | Western Regional Medical Center | 2015-04-01 |
| Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation Therapy (NCT02404818) | University of Florida | 2015-04-01 |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies (NCT02223052) | Celgene | 2014-10-27 |
| CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas (NCT02259556) | Chinese PLA General Hospital | 2014-10-01 |
| Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) (NCT02208037) | National Heart, Lung, and Blood Institute (NHLBI) | 2014-08-01 |
| Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients (NCT02164006) | TG Therapeutics, Inc. | 2014-06-11 |
| Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma (NCT02059239) | Weill Medical College of Cornell University | 2014-06-04 |
| Meloxicam vs Placebo for Mobilization (NCT02003625) | Massachusetts General Hospital | 2013-10-01 |
| An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies (NCT01929941) | Incyte Corporation | 2013-09-01 |
| A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma (NCT01877005) | The Lymphoma Academic Research Organisation | 2013-07-04 |
| Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers (NCT01597219) | University College, London | 2013-03-01 |
| Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma (NCT01788839) | Memorial Sloan Kettering Cancer Center | 2013-02-01 |
| Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies (NCT01767766) | TG Therapeutics, Inc. | 2013-01-07 |
| Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies (NCT01745913) | Weill Medical College of Cornell University | 2012-10-26 |
| An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) (NCT01742793) | Yale University | 2012-10-01 |
| Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant (NCT01699581) | Greg Monohan | 2012-09-01 |
| Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies (NCT01643603) | Barbara Ann Karmanos Cancer Institute | 2012-05-01 |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives (NCT01532635) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-03-01 |
| Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT01508312) | Memorial Sloan Kettering Cancer Center | 2012-01-05 |
| Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions (NCT01399931) | Ospedale Santa Croce-Carle Cuneo | 2012-01-01 |
| Reduced Intensity Double Umbilical Cord Blood Transplantation (NCT01408563) | Massachusetts General Hospital | 2011-12-01 |
| Communication Skills Intervention to Promote Transition Into Survivorship (NCT01483664) | Memorial Sloan Kettering Cancer Center | 2011-11-01 |
| Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide (NCT01342289) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2011-08-01 |
| Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma (NCT00816959) | American Scitech International | 2011-07-01 |
| Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma (NCT01884428) | Armando Santoro, MD | 2011-07-01 |
| FLT PET: A Pilot Study in Lymphoma Patients (NCT04028804) | The Hospital for Sick Children | 2011-07-01 |
| Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients (NCT01884441) | Armando Santoro, MD | 2011-07-01 |
| Whole-body MRI in Pediatric Hodgkin's Lymphoma (NCT04005703) | UMC Utrecht | 2011-06-01 |
| EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma (NCT01192464) | Baylor College of Medicine | 2011-05-10 |
| Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL (NCT01358747) | Centre Hospitalier Universitaire Dijon | 2011-05-01 |
| Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps (NCT01350258) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-04-01 |
| Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL) (NCT01300156) | National Cancer Center, Korea | 2011-02-01 |
| Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve Outcomes (NCT01304849) | Cancer Institute WIA | 2011-01-01 |
| Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation (NCT01203020) | West Virginia University | 2010-10-12 |
| SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) (NCT01402687) | Dana-Farber Cancer Institute | 2010-10-01 |
| Tandem Auto-Allo Transplant for Lymphoma (NCT01181271) | Massachusetts General Hospital | 2010-08-01 |
| Low Dose Chest Computed Tomography (CT) Screening (NCT01180010) | University Health Network, Toronto | 2010-08-01 |
| A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL) (NCT01034163) | Novartis Pharmaceuticals | 2010-06-01 |
| Mozobil for Autologous Stem Cell Mobilization (NCT01164345) | Sheba Medical Center | 2010-06-01 |
| Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT (NCT01478191) | Fondazione Italiana Linfomi - ETS | 2010-05-01 |
| Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation (NCT00984165) | National Cancer Institute (NCI) | 2010-01-19 |
| Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma (NCT01037478) | 4SC AG | 2009-12-01 |
| Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma (NCT01032148) | Roswell Park Cancer Institute | 2009-12-01 |
| Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy (NCT00963495) | University Health Network, Toronto | 2009-08-01 |
| Endothelial Function and IMT in Survivors of Hodgkin's Lymphoma (NCT00428688) | Sheba Medical Center | 2009-07-01 |
| Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory (NCT00879528) | Fondazione Italiana Linfomi - ETS | 2009-05-01 |
| A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma (NCT00866333) | Syndax Pharmaceuticals | 2009-04-13 |
| Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma (NCT00838955) | Loyola University | 2009-01-01 |
| Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma (NCT00901303) | Weill Medical College of Cornell University | 2008-10-01 |
| Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies (NCT00670592) | Novartis Pharmaceuticals | 2008-03-01 |
| Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma (NCT00792467) | Italfarmaco | 2008-02-01 |
| Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat (NCT00791011) | Amgen | 2008-02-01 |
| Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System (NCT00520130) | National Cancer Institute (NCI) | 2007-10-30 |
| Positron Emission Tomography(PET) in Lymphoma Assessment (NCT00887718) | University Health Network, Toronto | 2007-08-01 |
| Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant (NCT00510315) | Memorial Sloan Kettering Cancer Center | 2007-07-01 |
| phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients (NCT00496431) | Italfarmaco | 2007-05-01 |
| Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies (NCT00481871) | Acrotech Biopharma Inc. | 2007-05-01 |
| Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation (NCT00626626) | Milton S. Hershey Medical Center | 2007-05-01 |
| Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma (NCT00358982) | Mirati Therapeutics Inc. | 2006-08-01 |
| Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma (NCT00352027) | St. Jude Children's Research Hospital | 2006-07-20 |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma (NCT00359892) | Gemin X | 2006-07-01 |
| Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma (NCT00441818) | Tanox | 2006-05-01 |
| Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) (NCT00285259) | Astellas Pharma Inc | 2006-01-31 |
| Study of Immune Response Modifier in the Treatment of Hematologic Malignancies (NCT00276159) | Masonic Cancer Center, University of Minnesota | 2006-01-01 |
| Trial of AVN-944 in Patients With Advanced Hematologic Malignancies (NCT00273936) | Vertex Pharmaceuticals Incorporated | 2006-01-01 |
| A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma (NCT00283439) | Amgen | 2005-10-01 |
| CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation (NCT00333190) | Dana-Farber Cancer Institute | 2005-09-01 |
| Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies (NCT00143559) | St. Jude Children's Research Hospital | 2005-08-01 |
| Unrelated Donor Stem Cell Transplantation (NCT01364363) | Scripps Health | 2005-03-01 |
| Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma (NCT00284271) | University of Cologne | 2004-01-01 |
| Pegfilgrastim PBPC Mobilization Study (NCT00066092) | Amgen | 2003-04-01 |
| Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma (NCT00061672) | Abbott | 2003-04-01 |
| Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders (NCT00533923) | Beth Israel Deaconess Medical Center | 2002-12-01 |
| Nonmyeloablative Allogeneic Transplant (NCT01272817) | Scripps Health | 2001-10-01 |
| Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease (NCT00388349) | Stanford University | 2001-09-01 |
| HD11 for Intermediate Stages (NCT00264953) | University of Cologne | 1998-05-01 |
| HD10 for Early Stages (NCT00265018) | University of Cologne | 1998-05-01 |